[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350549-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350549-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-prrg1-as-a-possible-molecular-target-of-pancreatic-cancer","Identification of PRRG1 as a possible molecular target of pancreatic cancer","","The study investigates PRRG1 expression patterns, biological functions, and molecular mechanisms in pancreatic cancer pathogenesis. Bioinformatics and experimental validation show PRRG1 is markedly upregulated in pancreatic cancer tissues and correlates with poor prognosis and advanced grade. PRRG1 knockdown suppresses malignant phenotypes, whereas PRRG1 overexpression enhances them. Mechanistically, PRRG1 activates PI3K-Akt signaling via KLF4-mediated transcription, and single-cell data link PRRG1-high cells to immunosuppressive tumor microenvironment changes. Low-dose warfarin reduces PRRG1 and reverses tumor microenvironment effects in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-prrg1-as-a-possible-molecular-target-of-pancreatic-cancer/350549/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-prrg1-as-a-possible-molecular-target-of-pancreatic-cancer/350549.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study identify about PRRG1 in pancreatic cancer?","Question",{"text":63,"@type":64},"PRRG1 is found to be markedly upregulated in pancreatic cancer tissues, with expression levels correlating with poor prognosis and advanced histological grade.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PRRG1 influence pancreatic cancer cell behavior?",{"text":68,"@type":64},"PRRG1 silencing suppresses malignant phenotypes such as viability, proliferation, migration, and invasion, while PRRG1 overexpression enhances these oncogenic behaviors in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"What signaling pathway and regulator connect PRRG1 to cancer progression?",{"text":72,"@type":64},"The PI3K-Akt signaling pathway is identified as a key downstream effector of PRRG1, and KLF4 is found to bind the PRRG1 promoter region for transcriptional regulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350549,1790133298,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nIdentiﬁcation of PRRG1 as a possible molecular target of pancreatic cancer  \nJia-Jie Chen 1,2,5, Xiao-Ren Zhu 3,4,5, Qian-Hui Gu 1,2, Yuan-Yuan Liu 3 ✉ and Min-Bin Chen 1,2 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | In this study, we investigated the expression patterns, biological functions, and molecular mechanisms of Proline-rich γ -carboxylated Gla protein 1 (PRRG1) in pancreatic cancer pathogenesis. Our bioinformatics analysis revealed that PRRG1 expression is markedly upregulated in human PC tissues compared to normal pancreatic tissues, with elevated levels signiﬁcantly correlating with poor prognosis and advanced histological grade. We veriﬁed the high expression of PRRG1 in pancreatic cancer tissue specimens and pancreatic cancer cell lines. Using established PC cell lines (CFPAC-1 and PATU-8988T), we demonstrated that shRNA-mediated PRRG1 silencing effectively suppressed malignant phenotypes, including cell viability, proliferation, migration, and invasion in vitro. Conversely, lentivirus-induced PRRG1 overexpression enhanced these oncogenic behaviors. RNA-sequencing analysis identiﬁed the PI3K-Akt signaling pathway as a key downstream effector of PRRG1, with pathway activation status directly correlating with PRRG1 expression levels. Mechanistically, we identiﬁed KLF4 as a critical transcription factor binding to the PRRG1 promoter region. In vivo, PRRG1 knockdown inhibited tumor growth and PI3K-Akt activation in subcutaneous xenograft models, while PRRG1 overexpression accelerated tumor progression. Low-dose warfarin (2uM) decreased the levels of PRRG1 and GAS6/AXL axis, markedly suppressed the pro-tumorigenic effects driven by PRRG1 overexpression in vitro and in vivo. Notably, single-cell sequencing analysis revealing high PRRG1 expression speciﬁcally in PC epithelial cells. These PRRG1-positive epithelial cells not only exhibited enriched PI3K-Akt signaling activity but also showed signiﬁcant interactions with macrophages and endothelial cells, which were further validated in immunocompetent models in vivo. However, warfarin effectively reversed the PRRG1 overexpression–driven changes in TME. In conclusion, our ﬁndings establish PRRG1 as a key driver of pancreatic cancer progression through PI3K/Akt pathway activation and KLF4-mediated transcriptional regulation. PRRG1 facilitates the establishment of a protumorigenic and immunosuppressive TME in PC. Low-dose warfarin signiﬁcantly suppressed the pro-tumorigenic effects and the |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| PRRG1 overexpression–driven alterations in the tumor immune microenvironment. |  |  |\n|  | Cell Death and Disease (2026)17:613; [https://doi.org/10.1038/s41419-026-08832-9](https://doi.org/10.1038/s41419-026-08832-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nPancreatic cancer (PC) is among the most aggressive and lethal human malignancies. Recent data indicate that the 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) remains dismal, at approximately 13% [1] . This poor prognosis is largely attributable to late-stage diagnosis in most patients, highlighting the critical need for improved early detection methods [2, 3] . Current non-surgical treatment modalities, including chemotherapy [4], radiotherapy [5], targeted therapy [6], immunotherapy [7] are signiﬁcantly limited by challenges, such as drug resistance and tumor immune evasion mechanisms. These clinical hurdles underscore the urgent necessity to identify novel molecular targets and develop more effective therapeutic strategies for this devastating disease.  \nVitamin K-dependent (VKD) proteins have emerged as crucial mediators of cancer progression [8–11] . These proteins undergo a unique γ-carboxylation modiﬁcation catalyzed by vitamin  \nK-dependent γ-glut","cbCain1RY9QlcZpO","https://ap.wps.com/l/cbCain1RY9QlcZpO","pdf",33283067,"English","# Introduction\n## Background on pancreatic cancer and treatment limitations\n## Role of vitamin K-dependent proteins and γ-carboxylation\n## TAM ligands (Protein S/Gas6) and warfarin rationale","[{\"question\":\"What does the study identify about PRRG1 in pancreatic cancer?\",\"answer\":\"PRRG1 is found to be markedly upregulated in pancreatic cancer tissues, with expression levels correlating with poor prognosis and advanced histological grade.\"},{\"question\":\"How does PRRG1 influence pancreatic cancer cell behavior?\",\"answer\":\"PRRG1 silencing suppresses malignant phenotypes such as viability, proliferation, migration, and invasion, while PRRG1 overexpression enhances these oncogenic behaviors in vitro.\"},{\"question\":\"What signaling pathway and regulator connect PRRG1 to cancer progression?\",\"answer\":\"The PI3K-Akt signaling pathway is identified as a key downstream effector of PRRG1, and KLF4 is found to bind the PRRG1 promoter region for transcriptional regulation.\"}]","Identification of PRRG1 as a possible molecular target of pancreatic cancer | PDF",1790089550,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10e010a6467dd79137782edd8c5dedad.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f96f9485544afd2d41a64b8c39f873c.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e23082203c0cb13d465c37a2853b762.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d62a8e33d6faa21af49b1b15c8ea2a9.webp",980,1301]